source
- Most FDA-approved drugs meet postmarketing study requirements, and advisory panel backs two peptides for bulk compoundingA recent analysis published in JAMA Network Open found that nearly nine out of ten drugs approved by the U.S. Food and Drug Administration have completed their postmarketing requirements or commitm…
- Merck CEO warns Congress that restricting US-China biotech deals could cost America its biotech leadershipMerck CEO Rob Davis told Congress and the Trump administration that limiting or cutting off US-China dealmaking would jeopardize US biotech leadership. He emphasized that collaboration with Chines…